Literature DB >> 26308430

Corticosteroid Therapy Benefits Septic Mice With Adrenal Insufficiency But Harms Septic Mice Without Adrenal Insufficiency.

Junting Ai1, Ling Guo, Zhong Zheng, Shu-Xia Wang, Bing Huang, Xiang-An Li.   

Abstract

OBJECTIVES: Corticosteroid therapy is frequently used in septic patients given the rationale that there is an increased demand for corticosteroid in sepsis, and up to 60% of severe septic patients experience adrenal insufficiency. However, the efficacy of corticosteroid therapy and whether the therapy should be based on the results of adrenal function testing are highly controversial. The lack of an adrenal insufficiency animal model and our poor understanding of the pathogenesis caused by adrenal insufficiency present significant barriers to address this long-standing clinical issue.
DESIGN: Prospective experimental study.
SETTING: University laboratory.
SUBJECTS: Scavenger receptor BI null and adrenal-specific scavenger receptor BI null mice.
INTERVENTIONS: Sepsis was induced by cecal ligation and puncture.
MEASUREMENTS AND MAIN RESULTS: Using scavenger receptor BI mice as the first relative adrenal insufficiency animal model, we found that corticosteroid therapy significantly improved the survival in cecal ligation and puncture-treated scavenger receptor BI mice but causes more septic death in wild-type mice. We identified a corticosteroid cocktail that provides effective protection 18 hours post cecal ligation and puncture; using adrenal-specific scavenger receptor BI mice as an inducible corticosteroid-deficient animal model, we found that inducible corticosteroid specifically suppresses interleukin-6 production without affecting tumor necrosis factor-α, nitric oxide, and interleukin-10 production. We further found that inducible corticosteroid does not induce peripheral lymphocyte apoptosis but promotes phagocytic activity of macrophages and neutrophils.
CONCLUSIONS: This study demonstrates that corticosteroid treatment benefits mice with adrenal insufficiency but harms mice without adrenal insufficiency. This study also reveals that inducible corticosteroid has both immunosuppressive and immunopermissive properties, suppressing interleukin-6 production, promoting phagocytosis of immune effector cells, but not inducing peripheral lymphocyte apoptosis. These findings support our hypothesis that corticosteroid is an effective therapy for a subgroup of septic patients with adrenal insufficiency but harms septic patients without adrenal insufficiency and encourage further efforts to test this hypothesis in clinic.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26308430     DOI: 10.1097/CCM.0000000000001264

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  SR-BI (Scavenger Receptor BI), Not LDL (Low-Density Lipoprotein) Receptor, Mediates Adrenal Stress Response-Brief Report.

Authors:  Misa Ito; Xiang Ye; Qian Wang; Ling Guo; Dan Hao; Deborah Howatt; Alan Daugherty; Lei Cai; Ryan Temel; Xiang-An Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-06-11       Impact factor: 8.311

2.  SR-BI (Scavenger Receptor Class B Type 1) Is Critical in Maintaining Normal T-Cell Development and Enhancing Thymic Regeneration.

Authors:  Zhong Zheng; Junting Ai; Ling Guo; Xiang Ye; Subbarao Bondada; Deborah Howatt; Alan Daugherty; Xiang-An Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

3.  BclI polymorphism of the glucocorticoid receptor and adrenal crisis in primary adrenal insufficiency.

Authors:  Kathrin Zopf; Kathrin R Frey; Tina Kienitz; Manfred Ventz; Britta Bauer; Marcus Quinkler
Journal:  Endocr Connect       Date:  2017-09-27       Impact factor: 3.335

4.  Cortisol and adrenal androgens as independent predictors of mortality in septic patients.

Authors:  Rocío De Castro; David Ruiz; Bernardo-Alio Lavín; Jose Ángel Lamsfus; Luis Vázquez; Coral Montalban; Gilberto Marcano; Raquel Sarabia; María Paz-Zulueta; Cristina Blanco; Miguel Santibáñez
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.